FOLD Amicus Therapeutics Inc
6,238
$9.69
$0.36
(3.86%)
| Watchers | 6,238 |
| 52-Wk Low | $9.02 |
| 52-Wk High | $14.57 |
| Market Cap | $2.76B |
| Volume | 1.32M |
| 52-Wk High | $14.57 |
| 52-Wk Low | $9.02 |
Evaluating Amicus Therapeutics: Insights From 6 Financial AnalystsBenzinga • about 24 hours ago
Latest Ratings for FOLD
DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jan 2022SVB LeerinkUpgradesMarket PerformOutperform Jan 2022Cantor FitzgeraldMaintainsOverweight
View More...
Share to Feed
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) shares fell 2.5% on Thursday . The company traded as low as $11.56 and last traded at $11.56. 79,464 shares traded hands during trading, a...
A month has gone by since the last earnings report for Amicus Therapeutics (FOLD). Shares have lost about 8.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...
This is a signal that FOLD's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
WuXi Biologics Reports Solid 2023 Annual Results WuXi Biologics Reports Solid 2023 Annual Results PR Newswire HONG KONG, March 26, 2024 Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross...
Amicus Therapeutics, Inc. (NASDAQ:FOLD Free Report) Research analysts at Zacks Research lifted their Q1 2024 earnings estimates for Amicus Therapeutics in a report issued on...
This is a signal that FOLD's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines...
This is a signal that FOLD's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
This is a signal that FOLD's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...